This blog will discuss some important aspects to consider to maximise patient retention on your flu clinical trials. For more ...

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C.

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

AstraZeneca’s (AZ) Voydeya (danicopan) has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on therapy for adults with the rare blood disorder paroxysmal ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug Eli Lilly’s amyloid plaque-targeting Alzheimer’s disease (AD) drug has been ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...

Johnson & Johnson (J&J) has announced that a subcutaneous (SC) formulation of Darzalex (daratumumab) has been approved by the European Commission (EC) as part of a combination treatment for newly ...

The healthcare communications industry is in ‘re-set’ mode. Challenges with resourcing and budgets mean in-house and agency teams must work harder and more collaboratively than ever to demonstrate ...

After the recent Paralympics, I can’t help but be in awe of the individuals who participated and achieved such amazing feats, despite having everyday challenges most of us can hardly comprehend. It is ...

My déjà vu was triggered by the Access to Medicines Foundation, which reported that, although many pharma companies have programmes to improve access to medicines in low- to middle-income countries, ...